ArticleScience China. Life sciences2023
FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.
Erratum issuedAbstract read
In one paragraph
Article in Science China. Life sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Multi-omic analysis of the liver-breast axis reveals key hepatic mediators of breast cancer progression.Science China. Life sciences · 2026Review
- A LINE-1 retrotransposon promotes SEMA3C expression as a cis-regulatory enhancer to sustain breast cancer stem cell survival.Science China. Life sciences · 2026Article
- PRR11 as a newly identified oncogenic driver in retinoblastoma.Science China. Life sciences · 2026Article
- USP7 protects histone H1.2 from proteasome-mediated degradation to facilitate DNA repair and pancreatic neuroendocrine neoplasms progression.Science China. Life sciences · 2026Article
- circSCAP-encoded SCAP-129aa mediates platinum resistance in triple-negative breast cancer via the PI3K/AKT pathway.Science China. Life sciences · 2026Article
- Targeting senescent cells in aged adipose tissue induced by ovarian cancer with the NF-κB inhibitor quercetin and resveratrol impedes the growth and metastasis of ovarian cancer.Science China. Life sciences · 2026Article
- A novel kinase inhibitor, Regorafenib, blocks EGFR-dependent signaling to repress tumour metastasis in human triple-negative breast cancers.Frontiers in cell and developmental biology · 2026Article
- Metformin sensitizes non-small cell lung cancer to CDK4/6 inhibitor treatment by reducing lysosomal trapping.Science China. Life sciences · 2026Article
- From mechanism to application: programmed cell death pathways in nanomedicine-driven cancer therapies.Bioactive materials · 2025Review
- The FSIP Family: Roles in Health and Cancer.Cancers · 2025Review
- Regulation and application of mScience China. Life sciences · 2025Review
- Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.Science China. Life sciences · 2024Article
- The p38/MAPK pathway as a therapeutic target to prevent therapeutic escape of breast cancer stem cells.Science China. Life sciences · 2024Article
- Early-onset and later-onset cancer: trends, risk factors, and prevention in Northern China.Science China. Life sciences · 2024Article
- The genomic and immunogenomic landscape of mechanics pathway informs clinical prognosis and response to mechanotherapy.Science China. Life sciences · 2024Article
- Elevated mRNA level indicates FSIP1 promotes EMT and gastric cancer progression by regulating fibroblasts in tumor microenvironment.Open medicine (Warsaw, Poland) · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors.
Guanglei Chen *Department of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Lisha Sun *Department of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Xi Gu *Department of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Liping Ai *Department of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Jie YangDepartment of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Zhan ZhangDepartment of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Pengjie HouDepartment of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Yining WangDepartment of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Xunyan OuDepartment of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Xiaofan JiangDepartment of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Xinbo QiaoDepartment of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Qingtian MaDepartment of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Nan NiuDepartment of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Jinqi XueDepartment of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Hao ZhangDepartment of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Yongliang YangSchool of Bioengineering, Dalian University of Technology, Dalian, 116024, China.
Caigang LiuDepartment of Oncology, Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, 110004, China. liucg@sj-hospital.org.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CDK4/6 inhibitors are routinely recommended agents for the treatment of advanced HR
Indexed as
Lung NeoplasmsTriple Negative Breast NeoplasmsCarrier ProteinsCell Cycle CheckpointsCell Line, TumorCell ProliferationCyclin-Dependent Kinase 4HumansSeminal Plasma ProteinsCarrier ProteinsCDK4 protein, humanCyclin-Dependent Kinase 4FSIP1 protein, humanSeminal Plasma ProteinsCDK4/6 inhibitorsFSIP1triple-negative breast cancer
Identifiers
PMID
37460715What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.